{"id":"NCT03315793","sponsor":"Shionogi","briefTitle":"A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder","officialTitle":"A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-04","primaryCompletion":"2019-11-08","completion":"2019-11-08","firstPosted":"2017-10-20","resultsPosted":"2021-01-05","lastUpdate":"2021-01-05"},"enrollment":149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Duloxetine Hydrochloride","otherNames":["LY248686"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine Hydrochloride","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.","primaryOutcome":{"measure":"Change From Baseline on the Children's Depression Rating Scale-Revised (CDRS-R) Total Score","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"Duloxetine","deltaMin":-21.03,"sd":2.04},{"arm":"Placebo","deltaMin":-22.42,"sd":2.05}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5587"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Nausea","Somnolence","Nasopharyngitis","Headache","Decreased appetite"]}}